Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors

被引:109
作者
Engelen, MJA
de Bruijn, HWA
Hollema, H
ten Koor, KA
Willemse, PHB
Aalders, JG
van der Zee, AGJ
机构
[1] Univ Groningen Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen Hosp, Dept Pathol, NL-9700 RB Groningen, Netherlands
[3] Univ Groningen Hosp, Dept Internal Med, Div Med Oncol, NL-9700 RB Groningen, Netherlands
关键词
D O I
10.1006/gyno.2000.5811
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. The goals of this study were to analyze preoperative serum levels of CA 125, carcinoembryonic antigen (CEA), and CA 19-9 in patients with borderline ovarian tumors and to investigate if routine assessment of these markers in follow-up may lead to earlier detection of recurrence. Methods. For patient identification a database was used, in which data from all patients treated for gynecologic malignancies in the Department of Gynecologic Oncology, University Hospital Groningen, The Netherlands, are compiled. Between 1982 and 1997, 44 patients with borderline ovarian tumors were identified. Clinical data and serum CA-125 and CEA levels were retrieved from the database. CA 19-9 levels were determined in retrospect in available stored preoperative (24 patients) and follow-up (43 patients) serum samples. Results. Preoperative CA 125 levels were elevated in 8 of 33 (24%), CEA levels in 3 of 32 (9%), and CA 19-9 levels in 11 of 24 (46%) cases. In patients with mucinous tumors preoperative CA 19-9 was more frequently elevated (8/14, 57%) than CA 125 (3/20, 15%) (P = 0.02) or CEA (2/18, 11%) (P = 0.02). Complete follow-up serum CA 125, CEA, and CA 19-9 levels were available for 43 of 44 patients. Median follow-up was 84 months (range, 22-204). During follow-up two patients (5%) had recurrent disease. In one patient CA 125 became elevated at the time of recurrence; in the other patient (in retrospect) the CA 19-9 level did not return to normal after surgery, but kept rising, preceding clinical symptoms of recurrence for 13 months. Conclusions. If one chooses to use serum markers in follow-up of mucinous borderline ovarian tumors CA 19-9 should be included. Measurement of serum tumor markers in the follow-up of patients with borderline ovarian tumors may lead to earlier detection of recurrence in only a very small proportion of patients, while the clinical value of earlier detection of recurrence remains to be established. (C) 2000 Academic Press.
引用
收藏
页码:16 / 20
页数:5
相关论文
共 16 条
[1]  
[Anonymous], 1971, Acta Obstet Gynecol Scand, V50, P1
[2]   CANCER-ASSOCIATED ANTIGEN CA-195 IN PATIENTS WITH MUCINOUS OVARIAN-TUMORS - A COMPARATIVE-ANALYSIS WITH CEA, TATI AND CA-125 IN SERUM SPECIMENS AND CYST FLUIDS [J].
DEBRUIJN, HWA ;
TENHOOR, KA ;
BOONSTRA, H ;
MARRINK, J ;
KRANS, M ;
AALDERS, JG .
TUMOR BIOLOGY, 1993, 14 (02) :105-115
[3]  
deBruijn HWA, 1997, CURR OPIN OBSTET GYN, V9, P8
[4]   THE CONCOMITANT DETERMINATION OF DIFFERENT TUMOR-MARKERS IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER AND BENIGN OVARIAN MASSES - RELEVANCE FOR DIFFERENTIAL-DIAGNOSIS [J].
GADDUCCI, A ;
FERDEGHINI, M ;
PRONTERA, C ;
MORETTI, L ;
MARIANI, G ;
BIANCHI, R ;
FIORETTI, P .
GYNECOLOGIC ONCOLOGY, 1992, 44 (02) :147-154
[5]  
International Federation of Gynecology and Obstetrics, 1987, AM J OBSTET GYNECOL, V156, P263
[6]   CA-125 IN GYNECOLOGICAL PATHOLOGY - A REVIEW [J].
KENEMANS, P ;
YEDEMA, CA ;
BON, GG ;
VONMENSDORFFPOUILLY, S .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1993, 49 (1-2) :115-124
[7]  
KURMAN RJ, 1994, BLAUSTEINS PATHOLOGY, P706
[8]   Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: Differential diagnosis between colonic and ovarian carcinomas as primary sites [J].
Lagendijk, JH ;
Mullink, H ;
Van Diest, PJ ;
Meijer, GA ;
Meijer, CJLM .
HUMAN PATHOLOGY, 1998, 29 (05) :491-497
[9]   A PROSPECTIVE-STUDY OF TUMOR-MARKERS CA-125 AND CA-19.9 IN PATIENTS WITH EPITHELIAL OVARIAN CARCINOMAS [J].
MOLINA, R ;
OJEDA, B ;
FILELLA, X ;
BORRAS, G ;
JO, J ;
MAS, E ;
LOPEZ, JJ ;
BALLESTA, A .
TUMOR BIOLOGY, 1992, 13 (5-6) :278-286
[10]  
MOTOYAMA T, 1990, CANCER-AM CANCER SOC, V66, P2628, DOI 10.1002/1097-0142(19901215)66:12<2628::AID-CNCR2820661227>3.0.CO